ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Wang, Zi-Xian; Cui, Chengxu; Yao, Jun; Zhang, Yanqiao; Li, Mengxia; Feng, Jifeng; Yang, Shujun; Fan, Yun; Shi, Jianhua; Zhang, Xizhi; Shen, Lin; Shu, Yongqian; Wang, Cailian; Dai, Tianyang; Mao, Teng; Chen, Long; Guo, Zengqing; Liu, Bo; Pan, Hongming; Cang, Shundong; Jiang, Yi; Wang, Junye; Ye, Min; Chen, Zhendong; Jiang, Da; Lin, Qin; Ren, Wei; Wang, Junsheng; Wu, Lin; Xu, Yong; Miao, Zhanhui; Sun, Meili; Xie, Conghua; Liu, Ying; Wang, Qifeng; Zhao, Lina; Li, Qi; Huang, Canhong; Jiang, Ke广东医学院; 广州医学院; 安徽医科大学; 华中科技大学; 吉林大学; 南昌大学; 南方医科大学; 汕头大学; 哈尔滨医科大学; 河北医科大学; 四川大学; 浙江大学; 郑州大学; 武汉大学; 厦门大学; 中国医科大学; 中国医学科学院; 中山大学; 1
Cancer Cell2022-3-14DOI: 10.1016/j.ccell.2022.02.007
139被引19阅读
引用收藏
分享

摘要

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naive advanced ESCC were randomized (1:1) to receive toripalimab or placebo in combination with paclitaxel plus cisplatin (TP) every 3 weeks for up to 6 cycles, followed by toripalimab or placebo maintenance. At the pre specified final analysis of progression-free survival (PFS), a significant improvement in PFS is observed for the toripalimab arm over the placebo arm (hazard ratio [HR] = 0.58; 95% CI, 0.46-0.74; p < 0.0001). The pre specified interim analysis of overall survival (OS) also reveals a significant OS improvement for patients treated with toripalimab plus TP over placebo plus TP (HR = 0.58; 95% CI, 0.43-0.78; p = 0.0004). The incidences of grade R3 treatment-emergent adverse events are similar between the two arms. Toripalimab plus TP significantly improves PFS and OS in patients with treatment-naive, advanced ESCC, with a manageable safety profile.

学科与关键词

关键词
1ST-LINE TREATMENTSAFETYPACLITAXELCISPLATINNIVOLUMABRECURRENTSURVIVALEFFICACYANTIBODYPLACEBO
相关
加载中…
  • Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis
    Zhang, Yangfeng; Li, Chunhui; Du, Kunpeng; Pengkhun, Nov; Huang, Zijian; Gong, Min; Li, Yanyang; Liu, Xiang; Li, Lilin; Wang, Duanyu; Wang, Changqian; Chen, Fengsheng*; Li, Jiqiang*Immunotherapy, 2023, 15(10): 737-750.被引 1
  • First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
    Song, Yan; Zhang, Bo; Xin, Dao; Kou, Xiaoge; Tan, Zhenbo; Zhang, Shu; Sun, Meili; Zhou, Jin; Fan, Min; Zhang, Ming; Song, Yongxiang; Li, Suyi; Yuan, Yuan; Zhuang, Wu; Zhang, Jingdong; Zhang, Li; Jiang, Hao; Gu, Kangsheng; Ye, Huangyang; Ke, Ying; Li, Jing; Wang, Qingyu; Zhu, Jun; Huang, Jing*Nature Medicine, 2023, 29(2).被引 25
  • Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
    Lu, Zhihao; Wang, Junye; Shu, Yongqian; Liu, Lianke; Kong, Li; Yang, Lei; Wang, Buhai; Sun, Guogui; Ji, Yinghua; Cao, Guochun; Liu, Hu; Cui, Tongjian; Li, Na; Qiu, Wensheng; Li, Gaofeng; Hou, Xinfang; Luo, Hui; Xue, Liying; Zhang, Yanqiao; Yue, Wenbin; Liu, Zheng; Wang, Xiuwen; Gao, Shegan; Pan, Yueyin; Galais, Marie-Pierre; Zaanan, Aziz; Ma, Zhuo; Li, Haoyu; Wang, Yan; Shen, Lin*BRITISH MEDICAL JOURNAL, 2022, 377: e068714.被引 127
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Cell
发表日期
2022-03-14
卷期
第 40 卷, 第 3 期
页码
277-+
DOI
10.1016/j.ccell.2022.02.007
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Guangdong Esophageal Cancer Institute Science and Technology Program [M201905]; National Natural Sci-ence Foundation of China [81872011, 82061160373]; Science and Technology Program of Guangdong [2019B020227002]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-036]; National Major Science AMP; Technology Major Projects [2017ZX09302009]; Shanghai Science and Technology Committee Technology Grant [17431900700]

作者

  • W

    Wang, Zi-Xian (第一作者)

  • C

    Cui, Chengxu

查看全部 81 位作者收起作者
  • Y

    Yao, Jun

  • Z

    Zhang, Yanqiao

  • L

    Li, Mengxia

  • F

    Feng, Jifeng

  • Y

    Yang, Shujun

  • F

    Fan, Yun

  • S

    Shi, Jianhua

  • Z

    Zhang, Xizhi

  • S

    Shen, Lin

  • S

    Shu, Yongqian

  • W

    Wang, Cailian

  • D

    Dai, Tianyang

  • M

    Mao, Teng

  • C

    Chen, Long

  • G

    Guo, Zengqing

  • L

    Liu, Bo

  • P

    Pan, Hongming

  • C

    Cang, Shundong

  • J

    Jiang, Yi

  • W

    Wang, Junye

  • Y

    Ye, Min

  • C

    Chen, Zhendong

  • J

    Jiang, Da

  • L

    Lin, Qin

  • R

    Ren, Wei

  • W

    Wang, Junsheng

  • W

    Wu, Lin

  • X

    Xu, Yong

  • M

    Miao, Zhanhui

  • S

    Sun, Meili

  • X

    Xie, Conghua

  • L

    Liu, Ying

  • W

    Wang, Qifeng

  • Z

    Zhao, Lina

  • L

    Li, Qi

  • H

    Huang, Canhong

  • J

    Jiang, Ke

  • Y

    Yang, Kunyu

  • L

    Li, Daojun

  • L

    Liu, Yunpeng

  • Z

    Zhu, Zhitu

  • C

    Chen, Rixin

  • J

    Jia, Liqun

  • L

    Li, Wei

  • L

    Liao, Wangjun

  • L

    Liu, Hong-Xu

  • M

    Ma, Daiyuan

  • M

    Ma, Jie

  • Q

    Qin, Yanru

  • S

    Shi, Zhihong

  • W

    Wei, Qichun

  • X

    Xiao, Ke

  • Z

    Zhang, Yan

  • Z

    Zhang, Ying

  • C

    Chen, Xin

  • D

    Dai, Guanghai

  • H

    He, Jianxing

  • L

    Li, Junhe

  • L

    Li, Guanghui

  • L

    Liu, Yong

  • L

    Liu, Zhihua

  • Y

    Yuan, Xianglin

  • Z

    Zhang, Junping

  • F

    Fu, Zhichao

  • H

    He, Yifu

  • J

    Ju, Fang

  • L

    Liu, Zheng

  • T

    Tang, Peng

  • W

    Wang, Tiejun

  • W

    Wang, Weibo

  • Z

    Zhang, Jing

  • L

    Luo, Xianming

  • T

    Tang, Xiongwen

  • M

    May, Rena

  • F

    Feng, Hui

  • Y

    Yao, Sheng

  • K

    Keegan, Patricia

  • X

    Xu, Rui-Hua

  • W

    Wang, Feng

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417